新闻BenzingaGSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma Benzinga 2026.10.26 15:34 (GMT+0) 在Benzinga上打开 其他新闻 NBA牵手Kalshi与Polymarket，正式进入预测市场 Chainlink推出新方案，机构托管资产可直接参与DeFi借贷 纳指涨1.3%，AI相关股票上涨，英伟达上涨3.1% 巴克莱维持对百度的“与大盘持平”评级，将目标价下调至80美元 卢拉在决选中击败博索纳罗后，Nu 股票暴跌 巴克莱维持对美国运通的“平配”评级，将目标价下调至340美元
